Merck Serono ditches another multiple sclerosis candidate

Save

ONO-4641 is a sphingosine-1-phosphate (S1P) receptor agonist, like Novartis's Gilenya, which was launched in 2010. It met its primary endpoint of a reduction in the cumulative number of MRI lesions in a 407-patient Phase II trial in relapsing-remitting…